@article{1f924af9171e45b7a0217ca10a54c1e7,
title = "Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes",
abstract = "Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.",
keywords = "Antihyperglycemic, Cardiovascular outcome trials, Cardiovascular risk, Type 2 diabetes",
author = "Chilton, {Robert J.} and Dungan, {Kathleen M.} and Shubrook, {Jay H.} and Umpierrez, {Guillermo E.}",
note = "Funding Information: RJC has been a consultant/advisor to AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eli Lilly & Co, Novo Nordisk, Takeda, Medtronic, and Pfizer. GEU is partly supported by research grants from the National Institute of Health and National Center for Advancing Translational Science (UL1 RR025008), and 1P30DK111024-01 from the National Center for Research Resources. GEU has received unrestricted research support for inpatient studies (to Emory University) from Dexcom, Novo Nordisk, and Sanofi. KMD discloses research support from Sanofi Aventis, Novo Nordisk, Glaxo Smith Kline, AstraZeneca, consulting activities with Eli Lilly & Co, Sanofi Aventis, and MannKind. JHS serves as an advisor to Eli Lilly & Co, Novo Nordisk and Intarcia. Publisher Copyright: {\textcopyright} 2019 The Authors",
year = "2020",
month = jun,
doi = "10.1016/j.pcd.2019.09.008",
language = "English (US)",
volume = "14",
pages = "193--212",
journal = "Primary Care Diabetes",
issn = "1751-9918",
publisher = "Elsevier BV",
number = "3",
}